AI Article Synopsis
- Ovarian cancer is a serious illness that often leads to death in women and can resist treatment in many cases.
- Researchers are looking at how the immune system reacts to this type of cancer, focusing on special cells called T cells and substances called cytokines that can help predict how the disease progresses.
- The paper talks about new discoveries in how the immune system works against ovarian cancer and what this means for future treatments and understanding of the disease.
Article Abstract
Ovarian cancer is one of the leading causes of cancer-related death among women. Resistance to the disease occurs in more than 70% of the cases even after treated with chemotherapy agents such as paclitaxel- and platinum-based agents. The immune system is increasingly becoming a target for intense research in order to study the host's immune response against ovarian cancer. T cell populations, including NK T cells and Tregs, and cytokines have been associated with disease outcome, indicating their increasing clinical significance, having been associated with prognosis and as markers of disease progress, respectively. Harnessing the immune system capacity in order to induce antitumor response remains a major challenge. This paper examines the recent developments in our understanding of the mechanisms of development of the immune response in ovarian cancer as well as its prognostic significance and the existing experience in clinical studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034919 | PMC |
| http://dx.doi.org/10.1155/2010/791603 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!